Banga J Paul, Nielsen Claus H, Gilbert Jacqueline A, El Fassi Daniel, Hegedus Laszlo
Division of Gene and Cell Based Therapy, King's College London School of Medicine, London, United Kingdom.
Thyroid. 2008 Sep;18(9):973-81. doi: 10.1089/thy.2007.0406.
Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO.
目前大多数治疗格雷夫斯病的方法基本上是基于近50年前制定的方案。此外，对于甲状腺相关眼病（TAO）和皮肤病等并发症的治疗方法完全依赖于非特异性免疫抑制的传统方法。实验性格雷夫斯病诱导模型的最新进展，尽管由于缺乏甲状腺外表现而不完整，但为研究免疫干预策略提供了机会，包括对自身免疫过程中自身反应性B细胞和T细胞参与者的影响。这些重大进展为格雷夫斯病和TAO患者的治疗干预带来了新的可能性。
